通过实施集束化干预优化接受剖腹术的妇科癌症患者的输血实践
本研究为回顾性队列研究,旨在评估集束化干预能否降低卵巢癌和子宫内膜癌剖腹术患者的围手术期红细胞输血率。干预组89例(2015年9月28日至2016年5月31日)与历史对照组184例(2014年9月1日至2015年9月25日)比较,围手术期输血率干预组18.0%(16/89) vs 对照组41.3%(76/184),P<.001,降低56.4%;倾向性匹配后仍显著(16.2%[13/80] vs 36.2%[29/80],P=.004)。再入院率干预组1.1%(1/89) vs 对照组12.5%(23/184),P=.002,但匹配后未达统计学显著(1.2%[1/80] vs 7.5%[6/80],P=.12)。成本分析显示干预在住院期间加30天随访内成本中性。结论认为实施基于证据的标准化集束化干预与妇科肿瘤实践中输血减少相关。
要点
- 集束化干预与剖腹术妇科癌症患者围手术期输血率降低相关(18.0% vs 41.3%,P<.001)。
- 倾向性匹配后输血率改善仍显著(16.2% vs 36.2%,P=.004)。
- 再入院率匹配后未达统计学显著(1.2% vs 7.5%,P=.12),成本中性。
核心结论
- 应用基于证据的标准化集束化干预与妇科肿瘤实践中输血减少相关。
研究设计与样本
- 回顾性队列研究,比较干预组89例与历史对照组184例接受剖腹术的卵巢癌或子宫内膜癌患者。
- 干预组为2015年9月28日至2016年5月31日前瞻性数据定义的队列,对照组为2014年9月1日至2015年9月25日的历史对照。
- 干预包括基于美国麻醉医师协会指南的输血实践标准化、术中止血核查表、标准化术中液体状态沟通以及基于证据的氨甲环酸使用。
- 结局在未调整全队列和倾向性匹配队列中比较。
主要发现
- 干预组和对照组分别有89例和184例接受剖腹术,其中卵巢癌74例和152例,晚期子宫内膜癌15例和32例。
- 54例(60.7%)患者接受了氨甲环酸。
- 围手术期输血率干预组18.0%(16/89) vs 对照组41.3%(76/184),P<.001,降低56.4%。
- 倾向性匹配后输血率干预组16.2%(13/80) vs 对照组36.2%(29/80),P=.004。
- 再入院率干预组1.1%(1/89) vs 对照组12.5%(23/184),P=.002;倾向性匹配后干预组1.2%(1/80) vs 对照组7.5%(6/80),P=.12,未达统计学显著。
临床怎么用
- 作者认为应用基于证据的标准化集束化干预与妇科肿瘤实践中输血减少相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine blood transfusion practices and develop a standardized bundle of interventions to address the high rate of perioperative red blood cell transfusion among patients with ovarian and endometrial cancer. METHODS: This was a retrospective cohort study. Our primary aim was to determine whether an implemented bundled intervention was associated with a reduction in perioperative red blood cell transfusions among cases of laparotomy for cancer. Secondary aims included comparing perioperative demographic, surgical, complication, and cost data. Interventions included blood transfusion practice standardization using American Society of Anesthesiologists guidelines, an intraoperative hemostasis checklist, standardized intraoperative fluid status communication, and evidence-based use of tranexamic acid. Prospective data from women undergoing laparotomy for ovarian or endometrial cancer from September 28, 2015, to May 31, 2016, defined the study cohort and were compared with historical controls (September 1, 2014, to September 25, 2015). Outcomes were compared in the full unadjusted cohorts and in propensity-matched cohorts. RESULTS: In the intervention and historical cohorts, respectively, 89 and 184 women underwent laparotomy for ovarian cancer (n=74 and 152) or advanced endometrial cancer (n=15 and 32). Tranexamic acid was administered in 54 (60.7%) patients. The perioperative transfusion rate was lower for the intervention group compared with historical controls (18.0% [16/89] vs 41.3% [76/184], P<.001), a 56.4% reduction. This improvement in the intervention group remained significant after propensity matching (16.2% [13/80] vs 36.2% [29/80], P=.004). The hospital readmission rate was also lower for the intervention group compared with historical controls (1.1% [1/89] vs 12.5% [23/184], P=.002); however, this improvement did not attain statistical significance after propensity matching (1.2% [1/80] vs 7.5% [6/80], P=.12). Cost analysis demonstrated that this intervention was cost-neutral during index hospitalization plus 30-day follow-up. CONCLUSION: Application of a standardized bundle of evidence-based interventions was associated with reduced blood use in our gynecologic oncology practice.
引用
- Wallace SK, Halverson JW, Jankowski CJ, et al. Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol. 2018. PMID: 29630007. doi:10.1097/AOG.0000000000002463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。